PFS Longer With Abiraterone As Second-Line mCRPC Treatment

Second-line therapy with abiraterone plus prednisone versus cabazitaxel following initial docetaxel use in patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with longer clinical or radiographic progression-free survival (PFS), Spanish investigators reported at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.

Arancha Gonzalez del Alba, MD, of the Hospital Son Dureta, Palma de Mallorca, Spain, and colleagues, recruited 150 mCRPC patients as part of the prospective, multinational, observational CAPRO study, the primary endpoint of which was to describe the second-line management of mCRPC after docetaxel treatment in routine clinical practice. At a median follow-up of 7.8 months, 100 (67%) patients received abiraterone plus prednisone, 44 (29%) received cabazitaxel, and 6 (4%) received other treatments as second-line therapy.

The median clinical or radiologic PFS was significantly longer in the abiraterone than cabazitaxel group (8.7 vs 6.4 months). Compared with cabazitaxel recipients, the abiraterone-treated patients had a significant 44% lower risk of clinical or radiologic progression. The median biochemical progression-free survival was similar for the abiraterone and cabazitaxel groups (9.2 and 9.9 months, respectively), as was the proportion of patients who had a greater than 50% PSA response (47.3% and 32.3%, respectively).

See more coverage from the Genitourinary Cancers Symposium.

Reference

1. Del Alba AG, Puente J, Sala N, et al. Abireratone acetate plus prednisone and cabazitaxel as subsequent treatment after first-line docetaxel in metastatic castrate-resistant prostate cancer (mCRPC): Final efficacy and safety analysis of the CAPRO study. Data presented in poster format at the 2017 Genitourinary Cancers Symposium in Orlando, Florida. Poster Session B, Board D16. Abstract 276.